U.S. markets closed
  • S&P Futures

    4,070.00
    -11.75 (-0.29%)
     
  • Dow Futures

    34,348.00
    -81.00 (-0.24%)
     
  • Nasdaq Futures

    12,010.75
    -52.00 (-0.43%)
     
  • Russell 2000 Futures

    1,877.20
    -6.50 (-0.35%)
     
  • Crude Oil

    81.22
    0.00 (0.00%)
     
  • Gold

    1,810.90
    -4.30 (-0.24%)
     
  • Silver

    22.83
    -0.01 (-0.05%)
     
  • EUR/USD

    1.0527
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    3.5290
    -0.1740 (-4.70%)
     
  • Vix

    19.84
    -0.74 (-3.60%)
     
  • GBP/USD

    1.2246
    -0.0010 (-0.08%)
     
  • USD/JPY

    135.1000
    -0.2060 (-0.15%)
     
  • BTC-USD

    16,913.69
    -240.17 (-1.40%)
     
  • CMC Crypto 200

    400.34
    -5.81 (-1.43%)
     
  • FTSE 100

    7,558.49
    -14.56 (-0.19%)
     
  • Nikkei 225

    27,717.45
    -508.63 (-1.80%)
     

LogicBio's stock skyrockets after buyout bid for a 667% premium

LogicBio's stock skyrockets after buyout bid for a 667% premium

Shares of LogicBio Therapeutics Inc. skyrocketed more than seven-fold (up 643%) in morning trading, to bounce off the previous session's record low, after the genetic medicine company announced an agreement to be acquired by AstraZeneca PLC's Alexion, AstraZeneca Rare Disease in a deal that values LogicBio at about $68.23 million. The stock had closed Friday at a record low of 27 cents, representing a market capitalization for LogicBio of about $8.9 million. Under terms of the buyout deal, Alexi